ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TRVI vs SRPT // EV/EBITDA & P/E VALUATION

Trevi Therapeutics Inc. (NASDAQ) VS. Sarepta Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TRVI 2 — SRPT 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRVI VS. SRPT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TRVI SRPT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -23.70% -35.00% +11.30 TRVI /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -2.14% -15.14% +13.00 TRVI /fcf-yield <GO>
Operating Margin — -37.50% — TIE /operating-margins <GO>
Net Profit Margin — -38.30% — TIE /net-margins <GO>
Revenue Growth (YoY) — 4.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 SRPT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.7 51.2 -0.54 SRPT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.97B $2.03B -$63.6M SRPT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TRVI REV SRPT REV TRVI GROSS % SRPT GROSS % TRVI FCF SRPT FCF
FY 2025 $0 $1.86B — 98.0% -$42.1M -$307.5M
FY 2024 $0 $1.79B — — -$38.3M -$342.7M
FY 2023 $0 $1.14B — — -$31.7M -$501.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRVI // BETA —
SRPT // BETA —